"Misją Centrum Onkologii Ziemi Lubelskiej im. św. Jana z Dukli jest: Profesjonalne świadczenie pełnoprofilowych usług medycznych na rzecz Pacjenta Onkologicznego."

During the past decade, Centrum Onkologii Ziemi Lubelskiej im. SW. Jana z Dukli conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 14 clinical trials were completed, i.e. on average, 37.8% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 10 clinical trials were completed. i.e. 62.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centrum Onkologii Ziemi Lubelskiej im. SW. Jana z Dukli" #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Janssen Research & Development, LLC" with 5 trials sponsored, "BeiGene" with 4 trials sponsored, "Pfizer" with 4 trials sponsored and "Loxo Oncology, Inc." with 4 trials sponsored. Other sponsors include 16 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centrum Onkologii Ziemi Lubelskiej im. SW. Jana z Dukli" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "Takeda Development Center Americas, Inc." with 2 trials as a collaborator, "Bioscience, S.A." with 1 trials as a collaborator, "Braster S.A." with 1 trials as a collaborator and "EMD Serono" with 1 trials as a collaborator. Other collaborators include 2 different institutions and companies that were collaborators in the rest 12 trials.

According to Clinical.Site data, the most researched conditions in "Centrum Onkologii Ziemi Lubelskiej im. SW. Jana z Dukli" are "Breast Cancer" (4 trials), "Multiple Myeloma" (4 trials), "Renal Cell Carcinoma" (4 trials), "Chronic Lymphocytic Leukemia" (3 trials) and "Small Lymphocytic Lymphoma" (3 trials). Many other conditions were trialed in "Centrum Onkologii Ziemi Lubelskiej im. SW. Jana z Dukli" in a lesser frequency.

Most popular intervention types in "Centrum Onkologii Ziemi Lubelskiej im. SW. Jana z Dukli" are "Drug" (37 trials), "Biological" (6 trials), "Other" (4 trials) and "Device" (2 trials). Other intervention types were less common.

The name of intervention was led by "Rituximab" (5 trials), "Bendamustine" (4 trials), "Dexamethasone" (4 trials), "Placebo" (4 trials) and "Azacitidine" (3 trials). Other intervention names were less common.

The vast majority of trials in "Centrum Onkologii Ziemi Lubelskiej im. SW. Jana z Dukli" are 35 trials for "All" genders and 8 trials for "Female" genders.

Currently, there are NaN active trials in "Centrum Onkologii Ziemi Lubelskiej im. SW. Jana z Dukli". undefined are not yet recruiting, 13 are recruiting, 14 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Centrum Onkologii Ziemi Lubelskiej im. SW. Jana z Dukli, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Centrum Onkologii Ziemi Lubelskiej im. SW. Jana z Dukli, 2 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".

Centrum Onkologii Ziemi Lubelskiej im. SW. Jana z Dukli has several departments that took part in Clinical trials: "COZL Oddzial Onkologii Klinicznej z pododdzialem Chemioterapii Dziennej" - 15 trials, "Centrum Onkologii Ziemi Lubelskiej im. Sw. Jana z Dukli, Oddzial Hematologiczny" - 3 trials, "Ziemia Lubelska Oncological Center, Lublin" - 2 trials, "CENTRUM ONKOLOGII ZIEMI LUBELSKIEJ IM. ŚW. JANA Z DUKLI; II Oddział Onkologii Klinicznej" - 2 trials